Semaglutide Effects on Metabolic Outcomes in Diabetes Mellitus Patients — Real World Study
| dc.contributor.author | Balcázar Valencia, Carlos Mario | |
| dc.contributor.author | García Ramos, Andrés Felipe | |
| dc.contributor.author | Osorio Toro, Luis Miguel | |
| dc.contributor.author | Ordoñez Guzmán, Yessica Alejandra | |
| dc.contributor.author | Buitrago Gómez, Nathalia | |
| dc.contributor.author | Cabarcas López, William Fernando | |
| dc.contributor.author | Vizcaino Guerrero, Carlos Javier | |
| dc.contributor.author | Daza Arana, Jorge Enrique | |
| dc.contributor.author | Ramírez Rincón, Alex | |
| dc.contributor.author | Restrepo Erazo, Katherine | |
| dc.date.accessioned | 2025-07-10T22:11:11Z | |
| dc.date.available | 2025-07-10T22:11:11Z | |
| dc.date.issued | 2024 | |
| dc.description.abstract | Purpose: Diabetes is a public health problem that requires strategies to impact glycemic control and reduce the risk of long-term medical complications. Pharmacological management is a necessary treatment for this disease. Therefore, semaglutide is an essential tool to achieve the treatment targets. The present study aimed to evaluate the semaglutide effects on a cohort with type 2 diabetes mellitus (T2DM) in Colombia. Materials and Methods: The cohort included 49 patients with T2DM that have been treated in a specialized care center. Their glycemic outcomes, weight, renal function, and adverse events were evaluated through a 3-, 6-and 12-month follow-up. Results: Significant differences were observed in the outcome evaluation: reduction of glycated hemoglobin levels (MD −2.74 CI −1.95 to −3.52 in 6 months), fasting plasma glucose levels, body weight (MD −7.11 CI −5.97 to −8.24), and the albumin-to-creatinine ratio. The results were maintained throughout the treatment period. The adverse event rate was 16.3%, predominating gastrointestinal events. Conclusion: This real-world evidence shows the efficacy of semaglutide in achieving treatment goals in patients with T2DM. | |
| dc.identifier.citation | Balcázar-Valencia, C. M., García-Ramos, A. F., Osorio-Toro, L. M., Ordoñez-Guzmán, Y. A., Buitrago-Gómez, N., Cabarcas-López, W. F., Vizcaino-Guerrero, C. J., Daza-Arana, J. E., Ramírez-Rincón, A., & Restrepo-Erazo, K. (2024). Semaglutide Effects on Metabolic Outcomes in Diabetes Mellitus Patients — Real World Study. Diabetes, Metabolic Syndrome and Obesity , 17, 1667–1673. https://doi.org/10.2147/DMSO.S443115 | |
| dc.identifier.issn | 11787007 | |
| dc.identifier.uri | https://repositorio.usc.edu.co/handle/20.500.12421/7387 | |
| dc.language.iso | en | |
| dc.publisher | Dove Medical Press Ltd | |
| dc.subject | diabetes mellitus | |
| dc.subject | glycated hemoglobin A | |
| dc.subject | glycemic control | |
| dc.subject | obesity | |
| dc.subject | semaglutide | |
| dc.title | Semaglutide Effects on Metabolic Outcomes in Diabetes Mellitus Patients — Real World Study | |
| dc.type | Article |
Files
Original bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- Semaglutide Effects on Metabolic Outcomes in Diabetes Mellitus Patients .pdf
- Size:
- 1.53 MB
- Format:
- Adobe Portable Document Format
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: